Associated Papers
Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy.
Duminuco A et al.
American Journal of Hematology, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Foth M et al.
Biorxiv : the Preprint Server for Biology, 2025
Ultra-deep targeted next-generation sequencing with peripheral blood in patients with vascular malformations: a cohort of 40 patients.
Mitamura S et al.
Molecular Biology Reports, 2025
CDK4 inhibition reduces proliferation and mineralization in MAP2K1+ melorheostosis: opening a pathway to treatment.
Maity J et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 2025
Genomic Evaluation of Canine Prostatic Carcinomas as a Model for the Human Disease: or 'UC or not UC - that is the question'.
Thomas R et al.
Veterinary and Comparative Oncology, 2025
Exploring the Genetic Landscape of Primary Marginal Zone Lymphoma of the Urinary Bladder.
Balestri I et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long-Term Exposure While Maintaining Efficacy.
Wojciechowska N et al.
Pediatric Blood & Cancer, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Asymmetric coevolution of the MEK-ERK binding interface.
Persikov AV et al.
The Journal of Biological Chemistry, 2025
Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Cosci I et al.
Pharmaceuticals (basel, Switzerland), 2025
Pathogenic mechanism of extracranial arteriovenous malformations: insights from clinical, pathological, and genetic analyses.
Hirose K et al.
Virchows Archiv : an International Journal of Pathology, 2025
Functional assays in Drosophila facilitate classification of variants of uncertain significance associated with rare diseases.
Mok JW et al.
Genome Research, 2025
Langerhans Cell Histiocytosis With MAP2K1E102_I103del Mutation Successfully Treated With Trametinib.
Lang M et al.
Ejhaem, 2025
Genotyping as Part of Routine Clinical Care-The Outcomes for a Large Paediatric Vascular Anomaly Cohort.
O'Sullivan S et al.
American Journal of Medical Genetics. Part A, 2025
Identification of Somatic Genetic Variants in Superficial Vascular Malformations by Liquid Biopsy in a Cohort of 88 Patients from a French Hospital.
El Sissy FN et al.
Molecular Diagnosis & Therapy, 2025
RAS Pathway Mutations and Therapeutics in Vascular Anomalies.
Alharbi S et al.
Pediatric Blood & Cancer, 2025
Effects of F53 hotspot mutations on the molecular dynamics of MEK1 protein and the binding of its FDA-approved inhibitors.
Vural BE et al.
International Journal of Biological Macromolecules, 2025
Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours.
Ebbelaar CF et al.
Ebiomedicine, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Multicenter In-House Evaluation of an Amplicon-Based Next-Generation Sequencing Panel for Comprehensive Molecular Profiling.
Jantus-Lewintre E et al.
Molecular Diagnosis & Therapy, 2025
Molecular Mutations in Histiocytosis: A Comprehensive Survey of Genetic Alterations.
Pai P et al.
Molecular Biotechnology, 2025
Unraveling melorheostosis: insights into clinical features, diagnosis, and treatment.
Bhattacharyya T
Jbmr Plus, 2025
Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.
Jamieson A et al.
Journal of Gynecologic Oncology, 2025
Beyond BRAFV600E: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children.
Tang X et al.
Cancer Medicine, 2024
Nuclear translocation of SIRT4 mediates deacetylation of U2AF2 to modulate renal fibrosis through alternative splicing-mediated upregulation of CCN2.
Yang G et al.
Elife, 2024
Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway.
Li H et al.
Npj Precision Oncology, 2024
MEK Inhibition in the Treatment of Congenital Langerhans Cell Histiocytosis: A Case Report and Review of the Literature.
Wojciechowska N et al.
Journal of Pediatric Hematology/oncology, 2024
Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma.
Ito Y et al.
Cancer Research, 2024
Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.
Brown J et al.
Research Square, 2024
Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting.
Kumbrink J et al.
Pathology Oncology Research : Por, 2024
Clinical, Morphological and Molecular Features of Spitz tumors.
Donati M et al.
Ceskoslovenska Patologie, 2024
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar ME et al.
Signal Transduction and Targeted Therapy, 2023
Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic Tumors With Activating Mutations in MAP2K1.
Fumero-Velázquez M et al.
The American Journal of Surgical Pathology, 2023
VEGF Secretion Drives Bone Formation in Classical MAP2K1+ Melorheostosis.
Allbritton-King JD et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A et al.
Molecular Cancer, 2023
MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives.
Ram T et al.
Rsc Medicinal Chemistry, 2023
Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel.
Mitiushkina NV et al.
Diagnostics (basel, Switzerland), 2023
Evolutionary history of MEK1 illuminates the nature of deleterious mutations.
Andrianova EP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
Aggarwal A et al.
Oncology (williston Park, N.y.), 2023
High-depth next-generation sequencing panel testing in the evaluation of arteriovenous malformations.
Hernandez PV et al.
American Journal of Medical Genetics. Part A, 2023
Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities.
Fleischmann J et al.
Pnas Nexus, 2023
Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.
Chen SS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Success of Trametinib in the Treatment of Langerhans Cell Histiocytosis With Novel MAPK Pathway Mutations.
Orr K et al.
Journal of Pediatric Hematology/oncology, 2023
Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care.
Liu A et al.
Hematology Reports, 2023